文献速递淋巴瘤浆细胞疾病

肥胖与其他癌症

Obesity and Other Cancers.
PubMed 文献 · J Clin Oncol · 2016-11-07

本文总结超重、肥胖与癌症风险及预后关系的证据,重点涉及前列腺癌死亡、血液系统恶性肿瘤和肾癌。2016年IARC更新认为避免体脂过多可降低多发性骨髓瘤风险的证据充分,而降低前列腺癌死亡或弥漫性大B细胞淋巴瘤风险的证据有限。较高体重指数与晚期前列腺癌及前列腺癌死亡风险增加相关,并与多数血液系统恶性肿瘤亚型生存较差呈剂量反应关系。

要点

  • 2016年IARC更新认为避免体脂过多降低多发性骨髓瘤风险的证据充分。
  • 较高体重指数与晚期前列腺癌及前列腺癌死亡风险增加相关,呈剂量反应关系。
  • 较高体重指数与多数血液系统恶性肿瘤亚型生存较差相关。

核心结论

  • 这些数据支持成年早期和后期肥胖所致癌症负担不断增加的证据,但诊断后体重管理作为改善生存策略的方式仍无定论。

研究设计与样本

  • 本文综述了队列中罕见终点的汇总分析,不论各原始研究报告的主要结果如何,以进一步降低发表偏倚风险。

主要发现

  • 较高体重指数与晚期前列腺癌风险增加及前列腺癌死亡风险增加相关,并与多数血液系统恶性肿瘤亚型生存较差相关,呈剂量反应关系。
  • 肾癌证据主要基于回顾性数据,支持透明细胞变异型患者的肥胖悖论;但基于人群的队列数据表明,入组时较高体重指数与较差的肾癌特异性生存相关。

关键数值与推荐

  • 2016年IARC更新将避免体脂过多降低多发性骨髓瘤风险的证据归类为充分。
  • 2016年IARC更新发现避免体脂过多降低前列腺癌死亡风险或弥漫性大B细胞淋巴瘤风险的证据有限。
  • 2002年IARC报告仅纳入肾癌,而2003年美国癌症协会前瞻性队列研究注意到了前列腺癌和血液系统恶性肿瘤死亡。

局限性

  • 肾癌证据主要基于回顾性数据。
  • 诊断后体重管理作为改善生存策略的方式仍无定论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Evidence on overweight, obesity, and an increased risk of cancer continues to accumulate and was updated in the 2016 handbook on weight control from the International Agency for Research on Cancer (IARC). The underlying primary data, together with dose-response meta-analysis and, finally, pooled analysis of individual participant data, add insight into the relation between obesity and cancer risk and prognosis. We summarize the evidence for mortality from prostate cancer, hematologic malignancies, and kidney cancer. Methods We reviewed pooled analysis of rare end points across cohorts, regardless of primary results reported from the individual studies, further reducing risk of publication bias. Of these cancer sites, only kidney cancer was included in the IARC 2002 report, although mortality from prostate cancer and hematologic malignancies was noted in the American Cancer Society prospective cohort study in 2003. The 2016 update from the IARC added details for prostate and hematologic malignancies, classifying the evidence as sufficient to conclude that avoiding excess body fatness lowers the risk of multiple myeloma but found that the evidence for it lowering the risk of prostate cancer mortality or diffuse large B-cell lymphoma was limited. Results A higher body mass index is associated with an increased risk of advanced prostate cancer and prostate cancer mortality and is associated with worse survival in most subtypes of hematologic malignancies, in a dose-response fashion. Evidence for kidney cancer is built mostly on retrospective data, which supports an obesity paradox in patients with the clear cell variant; however, population-based cohort data indicate that a higher cohort-entry body mass index is associated with worse kidney cancer-specific survival. Conclusion Together, these data add support to the evidence for a growing cancer burden caused by adiposity in both early adult and later adult life, yet leave open the question of the means of weight management after diagnosis as a strategy to improve survival.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yang L, Drake BF, Colditz GA, et al. Obesity and Other Cancers. J Clin Oncol. 2016. PMID: 27903157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。